Anti-inflammatory activity of fruit fractions in vitro, mediated through toll-like receptor 4 and 2 in the context of inflammatory bowel disease

Nutrients

Volumn 6, Issue 11, 2014, Pages 5265-5279

  Nasef, Noha Ahmed ^a   Mehta, Sunali ^a   Murray, Pamela ^a   Marlow, Gareth ^a   Ferguson, Lynnette R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Inflammation; Inflammatory bowel disease; Polyphenols; Toll Like receptors

Indexed keywords

POLYPHENOL; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PLANT EXTRACT; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DIET THERAPY; DOSE RESPONSE; FRACTIONATION; FRUIT; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASE; METABOLIC ACTIVATION; PROTEIN EXPRESSION; SCORING SYSTEM; SCREENING TEST; SIGNAL TRANSDUCTION; CHEMISTRY; HEK293 CELL LINE; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; METABOLISM;

BACTERIA (MICROORGANISMS); FEIJOA; RUBUS; RUBUS IDAEUS;

ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; HEK293 CELLS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LIPOPOLYSACCHARIDES; NF-KAPPA B; PLANT EXTRACTS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84936940418     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6115265     Document Type: Article

References (39)

1. Tsianos, E.V.; Katsanos, K. Do we really understand what the immunological disturbances in inflammatory bowel disease mean? World J. Gastroenterol.2009, 15, 521–525.
2. Takeuchi, O.; Akira, S. Pattern recognition receptors and inflammation. Cell2010, 140, 805–820.
3. Serhan, C.N.; Savill, J. Resolution of inflammation: The beginning programs the end. Nat. Immunol.2005, 6, 1191–1197.
4. Medzhitov, R. Inflammation 2010: New adventures of an old flame. Cell 2010, 140, 771–776.
5. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial damps cause inflammatory responses to injury. Nature2010, 464, 104–107.
6. Yu, M.; Wang, H.; Ding, A.; Golenbock, D.T.; Latz, E.; Czura, C.J.; Fenton, M.J.; Tracey, K.J.; Yang, H. Hmgb1 signals through Toll-like receptor (TLR) 4 and TLR 2. Shock2006, 26, 174–179.
7. Asea, A.; Rehli, M.; Kabingu, E.; Boch, J.A.; Baré, O.; Auron, P.E.; Stevenson, M.A.; Calderwood, S.K. Novel signal transduction pathway utilized by extracellular HSP70 role of Toll-like receptor (TLR) 2 and TLR 4. J. Biol. Chem.2002, 277, 15028–15034.
8. Fiocchi, C. Genes and “in-vironment”: How will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig. Dis.2013, 30, 2–11.
9. Cario, E.; Podolsky, D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR 3) and TLR 4 in inflammatory bowel disease. Infect. Immun.2000, 68, 7010–7017.
10. Abreu, M.T.; Vora, P.; Faure, E.; Thomas, L.S.; Arnold, E.T.; Arditi, M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J. Immunol.2001, 167, 1609–1616.
11. Otte, J.M.; Cario, E.; Podolsky, D.K. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology2004, 126, 1054–1070.
12. Hommes, D.W. Risks and benefits of biologic therapy for IBD. J. Pediatr. Gastroenterol. Nutr.2009, 48, 52–53.
13. Seow, C.H.; de Silva, S.; Kaplan, G.G.; Devlin, S.M.; Ghosh, S.; Panaccione, R. Managing the risks of IBD therapy. Curr. Gastroenterol. Rep.2009, 11, 509–517.
14. Li, F.X.; Verhoef, M.J.; Best, A.; Otley, A.; Hilsden, R.J. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: A canadian national survey. Can. J. Gastroenterol. 2005, 19, 567–573.
15. Bravo, L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 2009, 56, 317–333.
16. Del Rio, D.; Costa, L.; Lean, M.; Crozier, A. Polyphenols and health: What compounds are involved? Nutr. Metab. Cardiovasc. Dis. 2010, 20, 1–6.
17. Gonzalez, R.; Ballester, I.; Lopez-Posadas, R.; Suarez, M.; Zarzuelo, A.; Martinez-Augustin, O.; de Medina, F.S. Effects of flavonoids and other polyphenols on inflammation. Crit. Rev. Food Sci. Nutr.2011, 51, 331–362.
18. Priego, S.; Feddi, F.; Ferrer, P.; Mena, S.; Benlloch, M.; Ortega, A.; Carretero, J.; Obrador, E.; Asensi, M.; Estrela, J.M. et al. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl-2-and superoxide dismutase 2-dependent mechanism. Mol. Cancer Ther.2008, 7, 3330–3342.
19. Scalbert, A.; Manach, C.; Morand, C.; Remesy, C.; Jimenez, L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr.2005, 45, 287–306.
20. Scalbert, A.; Morand, C.; Manach, C.; Rémésy, C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomed. Pharmacother.2002, 56, 276–282.
21. Shapiro, H.; Singer, P.; Halpern, Z.; Bruck, R. Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut2007, 56, 426–436.
22. Sies, H. Polyphenols and health: Update and perspectives. Arch. Biochem. Biophys. 2010, 501, 2–5.
23. Bronstein, I.; Fortin, J.; Voyta, J.; Juo, R.; Edwards, B.; Olesen, C.; Lijam, N.; Kricka, L. Chemiluminescent reporter gene assays: Sensitive detection of the gus and seap gene products. Biotechniques1994, 17, 172–177.
24. Bumrungpert, A.; Kalpravidh, R.W.; Chitchumroonchokchai, C; Chuang, C.C.; West, T.; Kennedy, A.; McIntosh, M. Xanthones from mangosteen prevent lipopolysaccharide-mediated inflammation and insulin resistance in primary cultures of human adipocytes. J. Nutr.2009, 139, 1185-1191.
25. Bumrungpert, A.; Kalpravidh, R.W.; Suksamrarn, S.; Chaivisuthangkura, A.; Chitchumroonchokchai, C; Failla, M.L. Bioaccessibility, biotransformation, and transport of α-mangostin from Garcinia mangostana (mangosteen) using simulated digestion and Caco-2 human intestinal cells. Mol. Nutr. Food Res.2009, 53, 54-61.
26. Chen, L.-G.; Yang, L.-L.; Wang, C.-C. Anti-inflammatory activity of mangostins from Garcinia mangostana. Food Chem. Toxicol. 2008, 46, 688-693.
27. Pedraza-Chaverri, J.; Cárdenas-Rodríguez, N.; Orozco-Ibarra, M.; Pérez-Rojas, J.M. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem. Toxicol. 2008, 46, 3227-3239.
28. Vuotto, M.L.; Basile, A.; Moscatiello, V.; de Sole, P.; Castaldo-Cobianchi, R.; Laghi, E.; Ielpo, M.T.L. Antimicrobial and antioxidant activities of Feijoa sellowiana fruit. Int. J. Antimicrob. Agents2000, 13, 197-201.
29. Perez-Jimenez, J.; Neveu, V.; Vos, F.; Scalbert, A. Identification of the 100 richest dietary sources of polyphenols: An application of the phenol-explorer database. Eur. J. Clin. Nutr.2010, 64(Suppl. 3), 112-120.
30. Neto, C.C. Cranberry and its phytochemicals: A review of in vitro anticancer studies. J. Nutr. 2007, 137, 186-193.
31. Cario, E.; Gerken, G.; Podolsky, D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology2007, 132, 1359-1374.
32. Covert, M.W.; Leung, T.H.; Gaston, J.E.; Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-κb activation. Science2005, 309, 1854-1857.
33. Motohashi, N.; Kawase, M.; Shirataki, Y.; Tani, S.; Saito, S.; Sakagami, H.; Kurihara, T.; Nakashima, H.; Wolfard, K.; Mucsi, I. et al.Biological activity of feijoa peel extracts. Anticancer Res. 2000, 20, 4323-4330.
34. Giuseppe, R.; Corrado, T. Secondary metabolites from the leaves of feijoa sellowiana berg. Phytochemistry2004, 65, 2947-2951.
35. Rossi, A.; Rigano, D.; Pergola, C; Formisano, C; Basile, A.; Bramanti, P.; Senatore, F.; Sautebin, L. Inhibition of inducible nitric oxide synthase expression by an acetonic extract from Feijoa sellowiana berg fruits. J. Agric. Food Chem.2007, 55, 5053-5061.
36. Cario, E. Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol. 2008, 1, 62-66.
37. Neilson, A.; George, J.; Janle, E.; Mattes, R.; Rudolph, R.; Matusheski, N.; Ferruzzi, M. Influence of chocolate matrix composition on cocoa flavan-3-ol bioaccessibility in vitro and bioavailability in humans. J. Agric. Food Chem.2009, 57, 9418-9426.
38. Yang, C.S.; Sang, S.; Lambert, J.D.; Lee, M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food Res.2008, 52, 139-151.
39. Neilson, A.; Ferruzzi, M. Bioavailability and metabolism of bioactive compounds from foods. In Nutrition in the Prevention and Treatment of Disease, 3rd ed.; Coulston, A., Boushey, C., Ferruzzi, M., Eds.; Elsevier Inc.: Amsterdam, The Netherlands, 2012.